 | | Actual patient. Individual results may vary. | | | | THURSDAY, NOVEMBER 11, 2021 | | | | This is what we've learned after spending more than a year actively trying not to stare at our faces as we talk on Zoom: We're now deeply, intimately familiar with what we look like, and because of this, aesthetic providers are seeing an unprecedented spike in demand for non-invasive treatments. We all know about injections for the lips and smile lines, but there's a treatment type more people should know about: chin fillers. Restylane® Defyne, an FDA-approved filler to help smooth smile and laugh lines, is now available for chin augmentation and correction of mild to moderate chin retrusion.[i],[ii] Restylane® Defyne is the first and only chin filler to demonstrate results* in a wide range of patients† including people with all skin types§, male patients, and patients over the age of 52.[ii] | | What is chin retrusion? When the chin recedes back toward the neck (called "chin retrusion"), it can create an imbalance of facial features.[iii],[iv] Restylane® Defyne achieves an enhanced chin projection that helps to bring the entire face into proportion.[i],[iii],[iv] Be sure to talk to your aesthetic provider today about whether Restylane® Defyne is right for you. Learn more about Restylane® Defyne's chin fillers here. | | | READ MORE | *Based on primary analyses of the primary endpoint** for skin type§ subgroups and ad-hoc analyses for gender (male/female) and age (20-29, 30-50, and >50 years) subgroups at Week 12.
†Patient=Clinical trial subject
§Fitzpatrick skin types grouped for analysis (I-III, IV, and V-VI).
**≥1 grade improvement in chin projection based on the Galderma Chin Retrusion Scale (GCRS).
[i] Restylane® Defyne. Instructions for Use. Fort Worth, TX: Galderma Laboratories, L.P., 2021.
[ii] Data on file. 43USCH1702 Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2020.
[iii] Fanous N, et al. Estimating Implant Size in Chin Augmentation: A Simplified Approach. Can J Plast Surg. 2003;11(3):161-165.
[iv] Vanaman Wilson MJ, et al. Role of Nonsurgical Chin Augmentation in Full Face Rejuvenation: A Review and Our Experience. Dermatol Surg. 2018;44(7):985-993.
Important Safety Information
Indication: Restylane® Defyne is indicated for injection into the mid-to-deep dermis for correction of moderate to severe, deep facial wrinkles and folds (such as nasolabial folds) in patients over the age of 21. Restylane® Defyne is also indicated for injection into the mid-to deep dermis (subcutaneous and/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients with mild to moderate chin retrusion over the age of 21.
Restylane® Defyne contains traces of gram-positive bacterial protein and is contraindicated for patients with allergies to such material or for patients with severe allergies that have required in- hospital treatment. Restylane® Defyne should not be used by patients with bleeding disorders, with hypersensitivity to amide-type local anesthetics, such as lidocaine, or by women who are pregnant or breastfeeding.
The most commonly observed side effects include swelling, redness, pain, bruising, tenderness, lump formation, and itching at the injection site. Use at the site of skin sores, pimples, rashes, hives, cysts, or infection should be postponed until healing is complete.
This product should not be injected into the blood vessels as it may cause vascular occlusion, infarction, or embolic phenomena. Use with caution in patients recently treated with anticoagulant or platelet inhibitors to avoid bleeding and bruising.
Restylane® Defyne is available only through a licensed practitioner. Complete Instructions for Use are available at www.RestylaneUSA.com.
© 2021 Galderma Laboratories, L.P. All trademarks are the property of their respective owners. | | | |
No comments:
Post a Comment